Episodes
Wednesday Jul 17, 2024
Managing COPD: 2024 GOLD Guideline Updates and More
Wednesday Jul 17, 2024
Wednesday Jul 17, 2024
This episode is a collaboration between the ACCP Ambulatory Care Practice and Research Network (PRN) ... and iForumRx.org.
The treatment of COPD has evolved significant over the past few years. The GOLD classification system was recently changed with a greater focus on exacerbations, and the role of inhaled corticosteroids (ICS) is limited to those with evidence of inflammation. Pharmacists can play a critical and positive role in the lives of people with COPD by encouraging lifestyle changes, administering vaccines to immunize against respiratory illnesses, ensuring proper inhaler technique, and assisting with medication access.
Panelists: Melissa Lipari, PharmD, BCACP; Thomas Levi Lancaster, PharmD, BCACP, BC-ADM; and Rachel Basinger, PharmD, BCACP, CTTS, DipACLM
Produced by Rebecca Khaimova, PharmD, BCACP, CDCES and Anna K Love, PharmD, BCACP
Music by lemonmusicstudio from Pixabay
Friday Jun 28, 2024
Conquering Confusion: Could Metformin Reduce Dementia Risk?
Friday Jun 28, 2024
Friday Jun 28, 2024
Patients with diabetes mellitus are at increased risk of dementia; therefore, knowledge about medications and their possible impact on the development of dementia is critical. Historically, metformin has been the most frequently prescribed medication for type 2 diabetes. Does metformin impact the risk of dementia? Should providers be hesitant to prescribe … or discontinue metformin therapy?
Guest Authors: Benjamin King, PharmD, BCACP, Amber Lilly, PharmD, and Jordan Cloonan, PharmD
Music by Good Talk
Friday Jun 14, 2024
Complex Patient Case 5: Hypoglycemia and a Painful, Swollen Leg
Friday Jun 14, 2024
Friday Jun 14, 2024
Reason for Visit: Referred by her community pharmacist to see a medical professional after frequent reports of low blood glucose readings. This is her first visit to this family medicine office — her previous PCP retired over a year ago.
Guest Authors: Katherine A Owen, PharmD, and Allison Zeurn, PharmD, BCACP
Expert Panelists: Jennifer N. Clements, PharmD, BCPS, BCACP, CDCES, BC-ADM and Stefanie Nigro, PharmD, BCACP, CDCES
Music by Good Talk
Friday May 31, 2024
Top Ten Things Every Clinician Should Know About Pharmacogenomics
Friday May 31, 2024
Friday May 31, 2024
Pharmacogenomics (PGx) is a rapidly evolving field of precision medicine that studies how genetic variability influences drug response. PGx testing can improve patient care through personalized medication adjustments for a variety of conditions, including pain, mental health, cardiology, and oncology.
Guest Authors: Lauren Jackson, PharmD, MPH and Jacob Marler, PharmD, BCCCP
Music by Good Talk
Friday May 17, 2024
Driving + Older Adult + Medications = An Accident Waiting to Happen?
Friday May 17, 2024
Friday May 17, 2024
While driving autonomy plays a crucial role in supporting mobility, social connections, and access to healthcare, older adults face elevated risks on the road. Rigorously collected data would equip us to educate patients about potential dangers, help us engage in collaborative discussions with patients and providers about deprescribing, and improve road safety for this vulnerable demographic.
Guest Authors: Mary Eva McClure, PharmD and Tavajay Campbell, PharmD, BCACP, CDCES
Guest Expert: Michael Brodeur, PharmD, BCGP
Music by Good Talk
Friday May 03, 2024
Friday May 03, 2024
Emerging data suggests we may have been overzealous with systemic corticosteroid prescribing and that allowing patients to self-manage their exacerbations with steroid rescue therapy may be harmful. However, we can now identify a subgroup of COPD patients who might benefit from systemic corticosteroids to treat their exacerbation.
Guest Authors: Hope Shrader Sherman, PharmD and Maricar Conson, PharmD, BCACP
Music by Good Talk
Friday Apr 12, 2024
SDOH Matters Too! Patient and Care Team Perspectives on Screening for SDOH
Friday Apr 12, 2024
Friday Apr 12, 2024
Identifying and addressing the social determinants of health (SDOH) influences health outcomes and can positively impact health equity in our society. While health systems in the US are screening for SDOH more often, information on how to improve screening efficiency and effectiveness is lacking. A recently published study was designed to determine what patient and clinician factors are associated with early implementation of SDOH screening in primary care.
Guest Author: Sharmon P. Osae, PharmD, BCACP, CDCES
Music by: Good Talk
Friday Mar 29, 2024
Treating Depression and Anxiety: Dosing, Pharmacogenetics, and Our Learners
Friday Mar 29, 2024
Friday Mar 29, 2024
This episode is a collaboration between the ACCP Ambulatory Care Practice and Research Network (PRN) ... and iForumRx.org.
Mental illness is very common - 1 in 5 adults in the United States will have a mental illness during their lifetime. Every ambulatory care (and community) pharmacist should be confident in their ability to recognize mental health challenges and how to use medications in an optimal manner to treat them. This is a FOLLOW-UP conversation from the ACCP Annual Meeting program entitled Ambulatory Care PRN Focus Session — Breaking Down Depression and Anxiety Management for the Ambulatory Care Pharmacist.
Expert Panelists: Richard Silvia, PharmD, BCPP and Jordan Baye, PharmD, BCPS
Music by lemonmusicstudio from Pixabay
Friday Mar 29, 2024
Complex Patient Case 4: Diabetes, CKD, and Psoriasis
Friday Mar 29, 2024
Friday Mar 29, 2024
Reason for Visit: Referred by primary care provider to pharmacy services for education and management; diabetes not responding to oral therapy.
Guest Authors: Jillian Cerullo, PharmD and Michelle Gauvin, PharmD, BCACP, BCGP, CDCES
Expert Panelists: Jennifer Trujillo, PharmD, BCPS, CDCES, BC-ADM and Joshua Neumiller, PharmD, CDCES
Music by Good Talk
Friday Mar 15, 2024
Friday Mar 15, 2024
Weight extremes, a body-mass index (BMI) either very underweight or obese, are associated with increased all-cause mortality. Mortality attributable to obesity is caused by many secondary conditions like metabolic disorders and cardiovascular (CV) disease. Enter the glucagon-like peptide-1 (GLP-1) receptor agonists—initially approved in the treatment of type 2 diabetes— which induce significant weight loss regardless of diabetes status. But can a weight loss drug decrease CV mortality?
Guest Authors: Gregory Castelli, PharmD, BCPS, BC-ADM, CDCES and Drake Meaney, PharmD, BCPS
Music by Good Talk